Breaking News

Breaking News English needs Part Time campus Reporters.Please
Prof. Tariq Mansoor is presently serving as the Vice-Chancellor, Aligarh Muslim University, Aligarh. Previously he has also served as Principal, J.N. Medical College, Chief Medical Superintendent, J.N. Medical College Hospital and Chairman, Department of Surgery. He is also the member of Medical Council of India since March 2015 for a period of four years. He is product of the first batch of prestigious Our Lady of Fatima Higher Secondary School, Aligarh. During his school days he has served as House Captain as well as School Captain. He did his MBBS and MS in General Surgery from Jawaharlal Nehru Medical College, AMU, Aligarh. A surgeon by profession with special interest in Breast and Thyroid Diseases, Prof. Tariq Mansoor has 33 years of Teaching and 35 years of Clinical experience. He has 90 publications to his credit and has guided 49 Postgraduate Medical Students for their Thesis as Supervisor / Co-Supervisor

Osteoporosis drug may help reduce heart diseases

Osteoporosis drug may help reduce heart diseases

HONG KONG: A commonly used drug for treating osteoporosis or bone pain may also help reduce the risk of death by cardiovascular, heart attack and stroke, according to a study.

The report, published in Journal of Bone and Mineral Research, showed that the drug Alendronate could lower the risk of cardiovascular diseases by 67 per cent and heart attacks by 45 per cent within a year.

Intake of the drug also reduced the risk of stroke by 18 per cent within five years and 17 per cent within 10 years.

“Our findings show that Alendronate is potentially cardioprotective in hip fracture patients,” said Ching-Lung Cheung, from the University of Hong Kong.

“Physicians should consider prescribing Alendronate or other similar drugs to patients with hip fracture and patients should also have good compliance with Alendronate treatment, as this is not only good for your bones but also your heart,” Cheung added.

Alendronate belongs to a class of drugs called bisphosphonates and works by preventing bone breakdown and increasing bone density.

It is used for osteoporosis, osteogenesis imperfecta, and several other bone diseases.

The researchers collected data from 34,991 patients, diagnosed with hip fracture in 2005. Out of these 4,602 patients received osteoporosis treatment during follow up.

Due to excess cardiovascular adverse events, there is a worldwide crisis in the current treatment of osteoporosis with drug romosozumab.

In 2017, the US Food and Drug Administration (FDA) had rejected romosozumab and requested more data before reaching a decision.

The study, thus, has significant implications in clinical trial design of anti-osteoporosis medications, the researchers said.


Read More

from The Siasat Daily

No comments:

Post a Comment